Biotechnology industry news alert provided by U.S. Equity News. Abraxis BioScience, Inc. (Nasdaq: ABBI), an integrated, global biopharmaceutical company, today said it will host an R&D Investor Day on Tuesday, June 20, 2006 in New York, New York. Senior management will be in attendance and will present an overview of the company's pipeline and platform technologies, including updates on the ABRAXANE(R) oncology clinical program, including Phase 3 trials, the COROXANE(TM) cardiovascular clinical program, the nab(TM) technology platform with discussions about SPARC, and first-in-class technologies. British drug maker GlaxoSmithKline PLC said Thursday that the Food and Drug Administration approved an expanded use for its cancer drug Hycamtin. When used with the chemotherapy cisplatin, the drug is now approved to treat well-advanced cervical cancer that has spread to distant areas of the body and cannot be treated with surgery or radiation. The FDA approved the new use under a six-month priority review. The company submitted data showing that Hycamtin plus cisplatin increased patient survival by an average 9.4 months, compared with 6.5 months using cisplatin alone.
Cordis Corp., a unit of drug manufacturer Johnson & Johnson (NYSE: JNJ), said late Thursday it would appeal a federal court's decision to uphold a previous ruling that its stent product infringed on a Boston Scientific Corp. patent. Johnson & Johnson had asked the U.S. District Court in Delaware to overturn the 2005 verdict. The jury verdict had said Johnson & Johnson's Cypher stent product infringed up a Boston Scientific drug coating patent. NutraCea (OTCBB: NTRZ), a leader in stabilized rice bran research and technology, announced recently that its Mexican Patent Application entitled "Supportive Therapy for Diabetes, Hyperglycemia and Hypoglycemia" has been allowed by the Mexican Industrial Property Office. The original patent application was previously approved in the United States and in Europe in 2001 by the United States Patent and Trademark Office under patent # 6303586 B1.
About U.S. Equity News
U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com .
U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal.
